JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target

BioAtla, Inc. +6.71%

BioAtla, Inc.

BCAB

1.51

+6.71%

JMP Securities analyst Reni Benjamin reiterates BioAtla (NASDAQ: BCAB) with a Market Outperform and maintains $12 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via